A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
← catalyst calendarNCT07271667 · readout ≤ 468 d
Sponsored by Curis, Inc. (industry) · CRIS — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
108estimated
Sites
11
Countries
Italy, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-23 | actual | When the study began enrolling |
| Primary completion | Nov 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- B-cell Malignancies
Interventions
- Drug: Emavusertib
- Drug: Zanubrutinib — also filed as BRUKINSA®
Primary outcomes
what the primary-completion date above is the date OFCohort 1: Undetectable Measurable Residual Disease (uMRD) Rate
measured Up to approximately 23 months
Cohort 2: Overall Response Rate (ORR)
measured Up to approximately 23 months
Permalink · CRIS's whole pipeline · Catalyst calendar · Every registered study · What changed